• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Anaphylaxis and Severe Disseminated Intravascular Coagulation Due to Remdesivir.瑞德西韦导致的过敏反应和严重弥散性血管内凝血。
Intern Med. 2024 Mar 15;63(6):873-876. doi: 10.2169/internalmedicine.2994-23. Epub 2024 Jan 13.
2
COVID-19-associated coagulopathy and disseminated intravascular coagulation.COVID-19 相关凝血功能障碍和弥散性血管内凝血。
Int J Hematol. 2021 Jan;113(1):45-57. doi: 10.1007/s12185-020-03029-y. Epub 2020 Nov 7.
3
Coagulopathy in COVID-19.新型冠状病毒疾病中的凝血功能障碍。
J Thromb Haemost. 2020 Sep;18(9):2103-2109. doi: 10.1111/jth.14975. Epub 2020 Jul 21.
4
COVID-19 coagulopathy: is it disseminated intravascular coagulation?COVID-19 凝血功能障碍：是弥散性血管内凝血吗？
Intern Emerg Med. 2021 Mar;16(2):309-312. doi: 10.1007/s11739-020-02601-y. Epub 2020 Dec 24.
5
Use of Remdesivir in Myasthenia gravis and COVID-19.使用瑞德西韦治疗重症肌无力和 COVID-19。
Pharmacotherapy. 2021 Jun;41(6):546-550. doi: 10.1002/phar.2524. Epub 2021 Apr 27.
6
Late-onset pulmonary edema and disseminated intravascular coagulation due to latex anaphylaxis.迟发性肺水肿和弥漫性血管内凝血与乳胶过敏反应有关。
Aesthetic Plast Surg. 2010 Jun;34(3):394-6. doi: 10.1007/s00266-009-9412-2. Epub 2009 Sep 19.
7
Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.使用真实世界数据评估瑞德西韦治疗 2019 冠状病毒病相关不良反应。
Expert Opin Drug Saf. 2021 Dec;20(12):1559-1564. doi: 10.1080/14740338.2021.1962846. Epub 2021 Aug 5.
8
Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019.瑞德西韦治疗 2019 年冠状病毒引起的肝脏疾病。
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2835-2836. doi: 10.1016/j.cgh.2020.07.050. Epub 2020 Jul 25.
9
A Case Report for Severe COVID-19 in a 9-Year-Old Child Treated with Remdesivir and Dexamethasone.儿童 COVID-19 病例报告：瑞德西韦和地塞米松治疗 9 岁重症患儿
J Korean Med Sci. 2021 Jul 26;36(29):e203. doi: 10.3346/jkms.2021.36.e203.
10
Severe arterial thromboembolism in patients with Covid-19.Covid-19 患者的严重动脉血栓栓塞。
J Crit Care. 2020 Dec;60:106-110. doi: 10.1016/j.jcrc.2020.08.002. Epub 2020 Aug 8.

本文引用的文献

1
Platelet-activating factor as an endogenous cofactor of food anaphylaxis.血小板活化因子作为食物过敏反应的内源性辅助因子。
Biofactors. 2023 Sep-Oct;49(5):976-983. doi: 10.1002/biof.1956. Epub 2023 May 19.
2
Mechanisms of human drug-induced anaphylaxis.人类药物诱导过敏反应的机制。
J Allergy Clin Immunol. 2021 Apr;147(4):1133-1142. doi: 10.1016/j.jaci.2021.02.013.
3
Non-IgE-mediated anaphylaxis.非 IgE 介导的过敏反应。
J Allergy Clin Immunol. 2021 Apr;147(4):1123-1131. doi: 10.1016/j.jaci.2021.02.012.
4
Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis.新型冠状病毒肺炎患者弥散性血管内凝血的发生率及影响：一项系统评价和荟萃分析。
Thromb Res. 2021 May;201:23-29. doi: 10.1016/j.thromres.2021.02.010. Epub 2021 Feb 17.
5
Anaphylaxis Due to Remdesivir.瑞德西韦引起的过敏反应。
Antimicrob Agents Chemother. 2023 May 1;95(5). doi: 10.1128/AAC.00233-21. Epub 2021 Feb 16.
6
World allergy organization anaphylaxis guidance 2020.世界过敏组织2020年过敏反应指南
World Allergy Organ J. 2020 Oct 30;13(10):100472. doi: 10.1016/j.waojou.2020.100472. eCollection 2020 Oct.
7
COVID-19-associated coagulopathy and disseminated intravascular coagulation.COVID-19 相关凝血功能障碍和弥散性血管内凝血。
Int J Hematol. 2021 Jan;113(1):45-57. doi: 10.1007/s12185-020-03029-y. Epub 2020 Nov 7.
8
Clotting abnormalities in critically ill COVID-19 patients are inconsistent with overt disseminated intravascular coagulation.危重症COVID-19患者的凝血异常与明显的弥散性血管内凝血不一致。
Thromb Res. 2020 Dec;196:272-275. doi: 10.1016/j.thromres.2020.09.015. Epub 2020 Sep 13.
9
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
10
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.

瑞德西韦导致的过敏反应和严重弥散性血管内凝血。

Anaphylaxis and Severe Disseminated Intravascular Coagulation Due to Remdesivir.

机构信息

Internal Medicine, Karatsu Red Cross Hospital, Japan.

出版信息

Intern Med. 2024 Mar 15;63(6):873-876. doi: 10.2169/internalmedicine.2994-23. Epub 2024 Jan 13.

DOI:10.2169/internalmedicine.2994-23
PMID:38220191
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11008986/
Abstract

A 69-year-old woman suffering with multiple myeloma developed coronavirus disease 2019 (COVID-19). Shortly after administration of remdesivir, she presented with symptoms of facial flushing, wheezing, and hypoxemia. Subsequently, thrombocytopenia and hypofibrinogenemia rapidly manifested, leading to a diagnosis of enhanced fibrinolytic-type disseminated intravascular coagulopathy (DIC). This clinical presentation was considered an immediate hypersensitivity reaction with associated coagulation abnormalities induced by remdesivir. Although remdesivir is generally considered safe and efficacious in the treatment of COVID-19, physicians should remain vigilant regarding the potential for severe adverse events associated with this medication.

摘要

一位 69 岁的多发性骨髓瘤女性患者感染了 2019 年冠状病毒病（COVID-19）。在接受瑞德西韦治疗后不久，她出现面部潮红、喘息和低氧血症的症状。随后，迅速出现血小板减少症和低纤维蛋白原血症，导致增强型纤维蛋白溶解型弥散性血管内凝血（DIC）的诊断。这种临床表现被认为是瑞德西韦引起的立即过敏反应和相关的凝血异常。尽管瑞德西韦通常被认为在治疗 COVID-19 方面是安全有效的，但医生仍应警惕与该药物相关的严重不良事件的发生。